Darvadstrocel - TiGenix

Drug Profile

Darvadstrocel - TiGenix

Alternative Names: Alofisel; Cx 601

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellerix
  • Developer La Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz; Takeda; TiGenix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rectal fistula
  • No development reported Rectovaginal fistula

Most Recent Events

  • 16 Nov 2017 Cx 601 is now called darvadstrocel
  • 02 Nov 2017 TiGenix receives patent allowance for CX 601 in Europe
  • 23 Oct 2017 Darvadstrocel receives Orphan Drug status for Rectal fistula in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top